NCT01110356已完成4 期
A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age
Vifor Pharma1 个研究点 分布在 1 个国家目标入组 294 人开始时间: 2010年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 294
- 试验地点
- 1
- 主要终点
- To assess the efficacy of a single intravenous (IV) administration of FCM (1,000 mg) compared with placebo in improving fatigue symptoms in IDNA women of child bearing age.
研究概览
简要总结
research study of Ferric carboxymaltose to treat fatigue/exhaustion symptoms, believed to be due to iron deficiency.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent prior to study specific procedures.
- •Premenopausal, regularly menstruating women.
- •Age ≥18 years.
- •Body weight between 50 and 90 kg.
- •Haemoglobin ≥115 g/L.
- •Iron deficiency at screening defined as follows:
- •S-ferritin level <50 ng/mL, AND, TfS <20%, OR,
- •S-ferritin level <15 ng/mL.
- •Serum C-reactive protein:
- •<5 mg/L if not on oral contraception, OR,
- •<20 mg/L if use of oral contraception.
- •Minimum total score of 5 on the Piper Fatigue Scale (PFS) (mean of items 2 to 23).
- •Negative pregnancy test (serum human chorionic gonadotropin (hCG) at screening.
- •Normal levels of vitamin B12 and folic acid at screening.
- •Adequate contraception during the study period and for 1 month following study completion.
- •Availability and willingness to complete all study visits and procedures per protocol.
排除标准
- •Haemoglobin level <115 g/L.
- •Haemoglobinopathy.
- •Haemochromatose.
- •Major depressive disorder based on Patient Health Questionnaire (PHQ-9) (5 items with scores ≥2; one of which corresponds to question number 1 or 2).
- •Any active or unstable concurrent medical condition (e.g., cancer, renal dysfunction, liver dysfunction (aspartate aminotransferase (AST); alanine aminotransferase (ALT) >3-fold upper limit), angina (Class IV).
- •Known human immunodeficiency virus/acquired immunodeficiency syndrome, hepatitis B virus or hepatitis C virus infection.
- •Chronic inflammatory disease (e.g., rheumatoid arthritis; inflammatory bowel disease).
- •Documented history of clinically significant level of sleep apnoea defined as 5 or more episodes per hour of any type of apnoea.
- •Intake of concurrent medications that could interfere with physical or mental performance (e.g., antidepressive, antihistamines, narcotic or any chemotherapeutic agents known to cause drowsiness).
- •Important recent weight loss (>10% within the past month).
- •Body weight <50 kg or >90 kg.
- •Thyroid dysfunction, thyroid stimulating hormone >4 μU/mL.
- •Intake of iron preparations 4 weeks prior to screening.
- •Use of gestagens e.g., Implanon, Mirena, Depo-Provera for menstruation repression (see Section 7.7, Prohibited Therapy or Concomitant Treatment, page 35).
- •Known hypersensitivity to FCM or to any other iron preparation.
- •Pregnancy (positive hCG test at screening) or breast feeding.
- •Participation in any other interventional trial within 4 weeks prior to screening.
- •Inability to fully comprehend and/or perform study procedures or provide written consent in the Investigator's opinion.
- •Subject is not using adequate contraceptive precautions during the study and for up to 1 month after the last dose of the study medication. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner.
- •Subject previously has entered this study.
- •Subject will not be available for follow-up assessments.
研究组 & 干预措施
Saline
Placebo Comparator
干预措施: Saline (Other)
Ferinject
Experimental
干预措施: Ferinject (Drug)
结局指标
主要结局
To assess the efficacy of a single intravenous (IV) administration of FCM (1,000 mg) compared with placebo in improving fatigue symptoms in IDNA women of child bearing age.
时间窗: Day 56
次要结局
- To compare efficacy of a single IV application of FCM with that of placebo on change of iron status on Day 56 (i.e., proportion of subjects with haemoglobin (Hb) ≥12 g/dL; serum-ferritin (s-ferritin) ≥50 ng/mL; transferrin saturation (TfS) >20%).(Day 56)
- To determine the relationship between change in iron status (s-ferritin and TfS) and improvement of fatigue symptoms.(Day 56)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart FailureIron DeficiencyChronic Heart FailureNCT01394562Vifor Pharma174
已完成
3 期
To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency AnaemiaIron Deficiency AnemiaNCT03591406Vifor (International) Inc.371
已完成
3 期
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant WomenAnaemiaNCT01131624Vifor Pharma252
已完成
3 期
Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)Iron Deficiency AnaemiaChronic Kidney DiseaseNCT00994318Vifor Pharma626
已完成
4 期
Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron DeficiencyIron DeficiencyHeart FailureNCT02937454Vifor (International) Inc.1,132